Diabetic nephropathy and long-term treatment effects of rosiglitazone and enalapril in obese ZSF1 rats

Journal of Endocrinology

Volumn 210, Issue 3, 2011, Pages 293-308

  Bilan, Victor P ^a   Salah, Eman M ^a   Bastacky, Sheldon ^a   Jones, Huw B ^b   Mayers, Rachel M ^b   Zinker, Bradley ^c   Poucher, Simon M ^b   Tofovic, Stevan P ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b ASTRAZENECA   (United Kingdom)

^c BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 4; ENALAPRIL; GLUCOSE; ROSIGLITAZONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIOLE; ARTICLE; BLOOD PRESSURE; CHRONIC DRUG ADMINISTRATION; CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DRUG MECHANISM; DRUG MEGADOSE; FOOD INTAKE; GLOMERULOSCLEROSIS; GLOMERULUS; GLUCOSE HOMEOSTASIS; GLUCOSURIA; HEART VENTRICLE HYPERTROPHY; HISTOPATHOLOGY; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; KIDNEY FIBROSIS; KIDNEY HYPERTROPHY; KIDNEY INJURY; KIDNEY TUBULE DISORDER; LIVER INJURY; MALE; MESANGIUM; METABOLIC SYNDROME X; NEPHRITIS; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEINURIA; RAT; RENAL PROTECTION; TREATMENT RESPONSE; WEIGHT GAIN;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD GLUCOSE; BLOOD PRESSURE; BODY WEIGHT; DIABETIC NEPHROPATHIES; DISEASE MODELS, ANIMAL; ENALAPRIL; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY; LIVER; MALE; METABOLIC SYNDROME X; MYOCARDIUM; OBESITY; PPAR GAMMA; RATS; THIAZOLIDINEDIONES;

EID: 80052759436     PISSN: 00220795     EISSN: 14796805     Source Type: Journal    
DOI: 10.1530/JOE-11-0122     Document Type: Article

References (56)

1. Bae EH, Kim IJ, Ma SK & Kim SW 2010 Rosiglitazone prevents the progression of renal injury in DOCA-salt hypertensive rats. Hypertension Research 33 255-262.
2. Banz WJ, Iqbal MJ, Bollaert M, Chickris N, James B, Higginbotham DA, Peterson R & Murphy L 2007 Ginseng modifies the diabetic phenotype and gens associated with diabetes in the male ZDF rat. Phytomedicine 14 681-689.
3. Baylis C, Atzpodien EA, Freshour G & Engels K 2003 Peroxisome proliferator-activated receptor (gamma) agonist provides superior renal protection versus angiotensin-converting enzyme inhibition in a rat model of type 2 diabetes with obesity. Journal of Pharmacology and Experimental Therapeutics 307 854-860.
4. Baynes J & Murray DB 2009 Cardiac and renal function are progressively impaired with aging in Zucker diabetic fatty type II diabetic rats. Oxidative Medicine and Cellular Longevity 2 328-334.
5. Bell D & McDermott BJ 2005 Effects of rosiglitazone and interactions with growth-regulating factors in ventricular cell hypertrophy. European Journal of Pharmacology 508 69-76.
6. Brenner BM, Meyer TW& Hostetter TH 1982 Dietary protein intake and the progressive nature of kidney disease: the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. New England Journal of Medicine 307 652-659.
7. Brosius FC III, Alpers CE, Bottinger EP, Breyer MD, Coffman TM, Gurley SB, Harris RC, Kakoki M, Kretzler M, Leiter EH et al. 2009 Mouse models of diabetic nephropathy. Journal of the American Society of Nephrology 20 2503-2512.
8. Buckingham RE, Al-Barazanji KA, Toseland CD, Slaughter M, Connor SC, West A, Bond B, Turner NC & Clapham JC 1998 Peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats. Diabetes 47 1326-1334.
9. Chawla A, Schwarz EJ, Dimaculangan DD & Lazar MA 1994 Peroxisome proliferator-activated receptor (PPAR) gamma: adipose-predominant expression and induction early in adipocyte differentiation. Endocrinology 135 798-800.
10. Coimbra TM, Janssen U, Grone HJ, Ostendorf T, Kunter U, Schmidt H, Brabant G & Floege J 2000 Early events leading to renal injury in obese Zucker (fatty) rats with type II diabetes. Kidney International 57 167-182.
11. Festuccia WT, Laplante M, Brule S, Houde VP, Achouba A, Lachance D, Pedrosa ML, Silva ME, Guerra-Sa R, Couet J et al. 2009 Rosiglitazoneinduced heart remodelling is associated with enhanced turnover of myofibrillar protein and mTOR activation. Journal of Molecular and Cellular Cardiology 47 85-95.
12. Fioretto P, Caramori ML & Mauer M 2008 The kidney in diabetes: dynamic pathways of injury and repair. The Camillo Golgi Lecture 2007. Diabetologia 51 1347-1355.
13. Greaves P 2000 Histopathology of Preclinical Toxicity Studies: Interpretation and Relevance in Drug Safety Evaluation, 2nd edn, pp 584-586. Amsterdam: Elsevier Science.
14. Griffin KA, Abu-Naser M, Abu-Amarah I, Picken M, Williamson GA & Bidani AK 2007 Dynamic blood pressure load and nephropathy in the ZSF1 (fa/fa cp) model of type 2 diabetes. American Journal of Physiology. Renal Physiology 293 F1605-F1613.
15. Guan Y & Breyer MD 2001 Peroxisome proliferator-activated receptors (PPARs): novel therapeutic targets in renal disease. Kidney International 60 14-30.
16. Heyen JR, Blasi ER, Nikula K, Rocha R, Daust HA, Frierdich G, Van Vleet JF, De Ciechi P, McMahon EG & Rudolph AE 2002 Structural, functional, and molecular characterization of the SHHF model of heart failure. American Journal of Physiology. Heart and Circulatory Physiology 283 H1775-H1784.
17. Joshi D, Gupta R, Dubey A, Shiwalkar A, Pathak P, Gupta RC, Chauthaiwale V & Dutt C 2009 TRC4186, a novel AGE-breaker, improves diabetic cardiomyopathy and nephropathy in Ob-ZSF1 model of type 2 diabetes. Journal of Cardiovascular Pharmacology 54 72-81.
18. Kang JG, Park CY, Ihm SH, Yoo HJ, Park H, Rhee EJ,Won JC, Lee WY, Oh KW, Park SW et al. 2010 Mechanisms of adipose tissue redistribution with rosiglitazone treatment in various adipose depots. Metabolism 59 46-53.
19. Kelly IE, Han TS, Walsh K & Lean ME 1999 Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes. Diabetes Care 22 288-293.
20. Komajda M, McMurray JJ, Beck-Nielsen H, Gomis R, Hanefeld M, Pocock SJ, Curtis PS, Jones NP & Home PD 2010 Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. European Heart Journal 31 824-831.
21. Larkins RG & Dunlop ME 1992 The link between hyperglycaemia and diabetic nephropathy. Diabetologia 35 499-504.
22. Leoncini G, Viazzi F & Pontremoli R 2010 Chronic kidney disease and albuminuria in arterial hypertension. Current Hypertension Reports 12 335-341.
23. Liu HF, Guo LQ, Huang YY, Chen K, Tao JL, Li SM & Chen XW 2010 Thiazolidinedione attenuate proteinuria and glomerulosclerosis in adriamycin-induced nephropathy rats via slit diaphragm protection. Nephrology 15 75-83.
24. Ma LJ, Marcantoni C, Linton MF, Fazio S & Fogo AB 2001 Peroxisome proliferator-activated receptor-gamma agonist troglitazone protects against nondiabetic glomerulosclerosis in rats. Kidney International 59 1899-1910.
25. Marsh SA, Powell PC, Agarwal A, Dell'Italia LJ & Chatham JC 2007 Cardiovascular dysfunction in Zucker obese and Zucker diabetic fatty rats: role of hydronephrosis. American Journal of Physiology. Heart and Circulatory Physiology 293 H292-H298.
26. McCune SA, Jenkins JE, Stills HF, Park S, Radin MJ, Jurin RR & Hamlin RE 1990 Renal and heart function in the SHFF/Mcc-cp rat. In Frontiers in Diabetes Research Lessons from Animal Diabetes III, pp 397-401. Ed. E Shafrir. London: Smith-Gordon.
27. McCune SA, Radin MJ, Jenkins JE, Chu YY, Park S & Peterson RG 1994 SHFF/Mcc-facp rat model: effects of gender and genotype on age of expression of metabolic complications and congestive heart failure an on response to drug therapy. In Frontiers in Diabetes Research Lessons from Animal Diabetes V, pp 255-270. Ed. E Shafrir. London: Smith-Gordon.
28. Michaelis OEt, Patrick DH, Hansen CT, Canary JJ, Werner RM & Carswell N 1986 Insulin-independent diabetes mellitus (type II). Spontaneous hypertensive/NIH-corpulent rat. American Journal of Pathology 123 398-400.
29. Nicholas SB, Kawano Y, Wakino S, Collins AR & Hsueh WA 2001 Expression and function of peroxisome proliferator-activated receptorgamma in mesangial cells. Hypertension 37 722-727.
30. O'Donnell MP, Kasiske BL & Keane WF 1988 Glomerular hemodynamic and structural alterations in experimental diabetes mellitus. FASEB Journal 2 2339-2347.
31. Oltman CL, Davidson EP, Coppey LJ, Kleinschmidt TL, Lund DD & Yorek MA 2008a Attenuation of vascular/neural dysfunction in Zucker rats treated with enalapril or rosuvastatin. Obesity 16 82-89.
32. Oltman CL, Davidson EP, Coppey LJ, Kleinschmidt TL, Lund DD, Adebara ET & Yoerk MA 2008b Vascular and neuronal dysfunction in Zucker diabetic fatty rats: a difficult condition to reverse. Diabetes, Obesity & Metabolism 10 64-74.
33. Palm F, Liss P, Fasching A, Hansell P & Carlsson PO 2001 Transient glomerular hyperfiltration in the streptozotocin-diabetic Wistar Furth rat. Upsala Journal of Medical Sciences 106 175-182.
34. Peterson RG 2000 The Zucker diabetic fatty rat. In Animal Models of Diabetes: a Primer, pp 109-127. Eds AFS Anders & E Shafrir. Amsterdam, The Netherlands: Harwood Academic.
35. Prabhakar S, Starnes J, Shi S, Lonis B & Tran R 2007 Diabetic nephropathy is associated with oxidative stress and decreased renal nitric oxide production. Journal of the American Society of Nephrology 18 2945-2952.
36. Rafikova O, Salah EM & Tofovic SP 2008 Renal and metabolic effects of tempol in obese ZSF1 rats - distinct role for superoxide and hydrogen peroxide in diabetic renal injury. Metabolism 57 1434-1444.
37. Routh RE, Johnson JH & McCarthy KJ 2002 Troglitazone suppresses the secretion of type I collagen by mesangial cells in vitro. Kidney International 61 1365-1376.
38. Sarafidis PA, Georgianos PI & Lasaridis AN 2010 Review: PPAR-gamma agonism for cardiovascular and renal protection. Cardiovascular Therapeutics (In Press).
39. Setti G, Hayward A, Dessapt C, Barone F, Buckingham R, White K, Bilous R, Hiroshi K, Gruden G, Viberti G et al. 2010 Peroxisome proliferatoractivated receptor-gamma agonist rosiglitazone prevents albuminuria but not glomerulosclerosis in experimental diabetes. American Journal of Nephrology 32 393-402.
40. Shoghi KI, Finck BN, Schechtman KB, Sharp T, Herrero P, Gropler RJ & Weich MJ 2009 In vivo metabolic phenotyping of myocardial substarte metabolism in rodents: differential efficacy of metformin and rosiglitazone monotherapy. Circulation: Cardiovascular Imaging 2 373-381.
41. Tang SC, Leung JC, Chan LY, Cheng AS, Lan HY & Lai KN 2010 Renoprotection by rosiglitazone in accelerated type 2 diabetic nephropathy: role of STAT1 inhibition and nephrin restoration. American Journal of Nephrology 32 145-155.
42. Tanimoto M, Fan Q, Gohda T, Shike T, Makita Y & Tomino Y 2004 Effect of pioglitazone on the early stage of type 2 diabetic nephropathy in KK/Ta mice. Metabolism 53 1473-1479.
43. Tervaert TW, Mooyaart AL, Amann K, Cohen AH, Cook HT, Drachenberg CB, Ferrario F, Fogo AB, Haas M, de Heer E et al. 2010 Pathologic classification of diabetic nephropathy. Journal of the American Society of Nephrology 21 556-563.
44. Tofovic SP & Jackson EK 1999 Effects of long-term caffeine consumption on renal function in spontaneously hypertensive heart failure prone rats. Journal of Cardiovascular Pharmacology 33 360-366.
45. Tofovic SP & Jackson EK 2003 Rat models of the metabolic syndrome. Methods in Molecular Medicine 86 29-46.
46. Tofovic SP, Kusaka H, Kost CK Jr & Bastacky S 2000 Renal function and structure in diabetic, hypertensive, obese ZDF!SHHF-hybrid rats. Renal Failure 22 387-406.
47. Tofovic SP, Kost CK Jr, Jackson EK & Bastacky SI 2002 Long-term caffeine consumption exacerbates renal failure in obese, diabetic, ZSF1 (fa-fa(cp)) rats. Kidney International 61 1433-1444.
48. Tofovic SP, Bastacky SI & Jackson EK 2007 Gender-dependent metabolic and renal effects of 2-hydroxyestradiol in obese diabetic ZSF1 rats. Physiologist 50 10-16.
49. US Renal Data System 2008 USRDS Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda.
50. Velliquette RA, Ernsberger P & Koletsky RJ 2007 The SHROB (Koletsky) rat as a model for metabolic syndrome. In Animal Models of Diabetes, edn 2 , pp 185-207. Ed. E Shafrir. Boca Raton, FL, USA: CRC Press.
51. Vora JP, Zimsen SM, Houghton DC & Anderson S 1996 Evolution of metabolic and renal changes in the ZDF/Drt-fa rat model of type II diabetes. Journal of the American Society of Nephrology 7 113-117.
52. Wagstaff AJ & Goa KL 2002 Rosiglitazone: a review of its use in the management of type 2 diabetes mellitus. Drugs 62 1805-1837.
53. Woods LL 1993 Mechanisms of renal hemodynamic regulation in response to protein feeding. Kidney International 44 659-675.
54. Wu L, Wang R, De Champlain J & Wilson TW 2004 Beneficial and deleterious effects of rosiglitazone on hypertension development in spontaneously hypertensive rats. American Journal of Hypertension 17 749-756.
55. Yoshimoto T, Naruse M, Nishikawa M, Naruse K, Tanabe A, Seki T, Imaki T, Demura R, Aikawa E & Demura H 1997 Antihypertensive and vasculoand renoprotective effects of pioglitazone in genetically obese diabetic rats. American Journal of Physiology 272 E989-E996.
56. Zhang X, Jia Y, Jackson EK & Tofovic SP 2007 2-Methoxyestradiol and 2-ethoxyestradiol retard the progression of renal disease in aged, obese, diabetic ZSF1 rats. Journal of Cardiovascular Pharmacology 49 56-63.